(:CRTX)

Jul 27, 2022 08:01 am ET
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics’ go-forward growth strategy and development pipeline plans.
Jul 27, 2022 08:00 am ET
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company’s lysine gingipain inhibitor in development for the treatment of Alzheimer’s disease and indications with disease pathology associated with the keystone pathogen P. gingivalis. The study was a randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerabili
Jun 21, 2022 08:00 am ET
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after oral treatment.
Jun 13, 2022 08:00 am ET
Cortexyme Appoints June Bray to its Board of Directors
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors.
May 20, 2022 08:01 am ET
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company’s Board of Directors.
May 20, 2022 08:00 am ET
Cortexyme Successfully Completes Acquisition of Novosteo
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Novosteo stockholders now own approximately 15.5% of the combined company.
May 12, 2022 08:00 am ET
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at
May 10, 2022 08:00 am ET
Cortexyme Announces Agreement to Acquire Novosteo
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company. The transaction, which has been approved by the Boards of Directors of both companies, is expected to clos
May 06, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ: AGFY), CareDx, Inc. (NASDAQ: CDNA), Medallion Financial Corp. (NASDAQ: MFIN), and Cortexyme,...
May 01, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CareDx, Inc. (NASDAQ: CDNA), Medallion Financial Corp. (NASDAQ: MFIN), Cortexyme, Inc. (NASDAQ: CRTX), and Corcept...
Apr 28, 2022 12:01 pm ET
Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating Cortexyme, Inc. (NASDAQ: CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more about how they might recover those...
Apr 26, 2022 07:07 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme (CRTX) for Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm’s Attorneys
Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Apr 25, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Corcept, RBB, and Verra and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ: CRTX), Corcept Therapeutics, Inc. (NASDAQ: CORT), RBB Bancorp (NASDAQ: RBB), and Verra Mobility...
Apr 25, 2022 04:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
NEW YORK, April 25, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 25, 2022 11:00 am ET
Thinking about buying stock in Cortexyme, Borqs Technologies, Sundial Growers, Nokia, or Nordic American Tanker?
NEW YORK, April 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRTX, BRQS, SNDL, NOK, and NAT.
Apr 21, 2022 11:13 am ET
Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm BOSTON -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ: CRTX) for potential...
Apr 20, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, SelectQuote, Corcept, and Core Scientific and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ: CRTX), SelectQuote, Inc. (NYSE: SLQT), Corcept Therapeutics, Inc. (NASDAQ: CORT), and Core...
Apr 20, 2022 02:04 pm ET
CIR INVESTIGATION: Hagens Berman, National Trial Attorneys, Investigating Cortexyme (CRTX) for Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm
Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Apr 15, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and SelectQuote and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CareDx, Inc. (NASDAQ: CDNA), Medallion Financial Corp. (NASDAQ: MFIN), Cortexyme, Inc. (NASDAQ: CRTX), and SelectQuote, Inc....
Apr 15, 2022 09:16 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. (“Affirm” or the “Company”) (NASDAQ: CRTX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 13, 2022 12:43 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm
Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Apr 11, 2022 08:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 10, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Medallion, Cortexyme, SelectQuote, and Corcept and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Medallion Financial Corp. (NASDAQ: MFIN), Cortexyme, Inc. (NASDAQ: CRTX), SelectQuote, Inc. (NYSE: SLQT), and Corcept...
Apr 07, 2022 10:28 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm
Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now.   The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Apr 06, 2022 06:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. (“Affirm” or the “Company”) (NASDAQ: CRTX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 05, 2022 12:24 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public.
Mar 30, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Koppers, RBB, and SelectQuote and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ: CRTX), Koppers Holdings, Inc. (NYSE: KOP), RBB Bancorp (NYSE: KOP), and SelectQuote, Inc. (NYSE:...
Mar 28, 2022 10:33 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm
Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Mar 25, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Sea, Cortexyme, and RBB and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sea Limited (NYSE: SE), Cortexyme, Inc. (NASDAQ: CRTX), and RBB Bancorp (NASDAQ: RBB). Our investigations concern whether...
Mar 21, 2022 08:00 am ET
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, presented new target engagement and biomarker data from the GAIN Trial at the
Mar 19, 2022 10:05 am ET
CRTX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm
Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now.   The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Mar 18, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Sea, Cortexyme, FAT, and Koppers and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sea Limited (NYSE: SE), Cortexyme, Inc. (NASDAQ: CRTX), FAT Brands, Inc. (NASDAQ: FAT), and Koppers Holdings, Inc. (NYSE:...
Mar 15, 2022 08:00 am ET
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimer’s and dementia care, to the company’s Board of Directors.
Mar 14, 2022 09:27 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, FAT Brands, Koppers, and RBB and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ: CRTX), FAT Brands, Inc. (NASDAQ: FAT), Koppers Holdings, Inc. (NYSE: KOP), and RBB Bancorp (NASDAQ:...
Mar 14, 2022 08:00 am ET
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at the AD/PD™ 2022 Interna
Mar 09, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Sea Limited, Cortexyme, FAT, and Koppers and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sea Limited (NYSE: SE), Cortexyme, Inc. (NASDAQ: CRTX), FAT Brands, Inc. (NASDAQ: FAT), and Koppers Holdings, Inc. (NYSE:...
Mar 09, 2022 08:00 am ET
Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided an update on both proprietary preclinical research and peer-reviewed publications supporting the potential of atuzaginstat (COR388) to treat patients with high-risk oral potentially malignant disorders (OPMDs), including oral/head and neck squamous cell cancer (O/HNSCC), high-risk oral pre-malignant dysplasia (PmD), proliferative verrucous leukoplakia (PVL), and carcinoma-in-situ (CIS).
Mar 08, 2022 08:00 am ET
Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced results from the single ascending dose (SAD) portion of the Phase 1 clinical trial of its new drug candidate COR588, a next generation, oral, small-molecule lysine gingipain inhibitor in development for the treatment of diseases related to P. gingivalis infection. The SAD trial was designed to evaluate the safety and pharmacokinetics of COR588 in healthy volunteers.
Mar 07, 2022 05:12 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors to Inquire About Securities Class Action Investigation – CRTX
WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially...
Mar 04, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, FAT, and Koppers and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cortexyme, Inc. (NASDAQ: CRTX), FAT Brands, Inc. (NASDAQ: FAT), and Koppers Holdings, Inc. (NYSE: KOP). Our investigations...
Feb 27, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Informatica, C3.ai, and Cortexyme and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Informatica, Inc. (NYSE: INFA), C3.ai, Inc. (NYSE: AI), and Cortexyme, Inc. (NASDAQ: CRTX). Stockholders have until the...
Feb 25, 2022 08:45 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading...
Feb 24, 2022 09:00 pm ET
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) on behalf of Cortexyme stockholders. Our investigation concerns whether Cortexyme has violated the federal securities laws and/or engaged in other unlawful business practices.
Feb 23, 2022 09:00 pm ET
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) on behalf of Cortexyme stockholders. Our investigation concerns whether Cortexyme has violated the federal securities laws and/or engaged in other unlawful business practices.
Feb 18, 2022 10:37 am ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – CRTX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially...
Feb 15, 2022 11:11 am ET
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cortexyme, Inc. (“Cortexyme” or “the Company”) (NASDAQ:
Feb 14, 2022 08:33 pm ET
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cortexyme, Inc. (“Cortexyme” or “the Company”) (NASDAQ:
Feb 14, 2022 04:09 pm ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public.
Feb 14, 2022 11:48 am ET
Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating Cortexyme, Inc. (NASDAQ: CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more about how they might recover those...
Feb 01, 2022 08:01 am ET
Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today provided a business update and announced key milestones for 2022.
Feb 01, 2022 08:00 am ET
Cortexyme Announces Change in Executive Leadership Team
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that its board of directors has appointed Christopher Lowe, the company’s chief operating officer and chief financial officer, as interim chief executive officer, effective immediately. This appointment follows the departure of Casey Lynch as the company’s chief executive officer and chair of the board. Current independent board member David Lamond will replace Ms. Lynch as the chair of the board. Additionally, Cortexyme announced the departure of S
Jan 31, 2022 07:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jan 27, 2022 05:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 27, 2022 10:17 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Cortexyme, Inc. (CRTX) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cortexyme, Inc. ("Cortexyme" or "the Company") (NASDAQ: CRTX). Investors who purchased Cortexyme securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg
Jan 26, 2022 06:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jan 26, 2022 08:00 am ET
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that the company received a letter from the U.S. Food and Drug Administration (FDA) on January 25, 2022 placing a full clinical hold on atuzaginstat’s (COR388) Investigational New Drug application (IND 134303). The company plans to provide additional updates pending continued engagement with FDA.
Nov 23, 2021 08:00 am ET
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday, November 30, 2021, beginning at 1:25 p.m. Eastern Time.
Nov 11, 2021 11:30 am ET
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
Cortexyme, Inc. (Nasdaq: CRTX) will present additional data from its Phase 2/3 GAIN Trial at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program today, Thursday, November 11, 2021, at 11:35 a.m. Eastern Time taking place in Boston, Massachusetts, as well
Nov 04, 2021 08:00 am ET
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
Cortexyme, Inc. (Nasdaq: CRTX) announced that it will participate at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program on Thursday, November 11, 2021, at 11:35 a.m. Eastern Time in Boston, Massachusetts. During the company’s 30-minute presentation, Cortexyme’s chief medical officer Michael Detke, MD, PhD, and GAIN Trial lead investigator Marwan Sabbagh, MD, FAAN, will provide additional GAIN Trial top-line results and analysis.
Nov 04, 2021 04:33 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 04, 2021 02:39 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 03, 2021 11:15 am ET
Cortexyme, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are...
Nov 01, 2021 03:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX
Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 29, 2021 06:22 pm ET
Cortexyme Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At Cortexyme, Inc.
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Cortexyme, Inc. (“Cortexyme” or the “Company”) (Nasdaq: CRTX), a clinical stage biopharmaceutical company. On August 9, 2021, before the market...
Oct 27, 2021 10:00 am ET
Thinking about buying stock in Inspira Technologies, Vinco Ventures, Cortexyme, Enphase Energy, or BioNTech?
NEW YORK, Oct. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IINN, BBIG, CRTX, ENPH, and BNTX.
Oct 26, 2021 04:01 pm ET
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
Cortexyme, Inc. (Nasdaq: CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis). The
Sep 27, 2021 08:00 am ET
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer’s disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will participate at the upcoming 14th Clinical Trials on Alzheimer's Disease (CTAD 2021) conference scheduled for November 9-12, 2021, in Boston, Massachusetts, as well as virtually. Cortexyme will present results from its Phase 2/3 GAIN Trial evaluating the efficacy of its lead small molecule atuzaginstat in 643 mild to moderate Alzheimer’s patients. Cortexyme expects to announce top-line resul
Sep 08, 2021 08:00 am ET
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced that the first cohort of healthy participants have been dosed in the Phase 1 clinical trial of its new drug candidate, COR588. COR588 is a second-generation small-molecule lysine-gingipain inhibitor differentiated from the company’s lead drug candidate atuzaginstat (COR388) by its improved pharmacokinetic properties and anticipated once daily oral administration. Delivering o
Sep 07, 2021 08:00 am ET
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Casey Lynch, chief executive officer, co-founder, and chair, and Chris Lowe, chief operating officer and chief financial officer, will participate in a fireside chat at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually on Monday, September 13, 2021 at 7:00 a.m. Eastern Time.
Aug 25, 2021 08:00 am ET
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the presentation of new data demonstrating evidence of P. gingivalis infection of the central nervous system in Alzheimer’s disease at the
Aug 18, 2021 08:00 am ET
Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, will participate as a featured speaker covering its pivotal Phase 2/3 GAIN Trial of atuzaginstat and the upstream role that P. gingivalis plays in key pathologies of Alzheimer’s disease at the upcoming
Aug 09, 2021 08:00 am ET
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, today provided an update on expected clinical top-line data and reported second quarter 2021 financial results.
Aug 04, 2021 08:00 am ET
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate in a fireside chat at Canaccord Genuity' s 41st Annual Growth Conference taking place virtually on Wednesday, August 11, 2021 at 3:00 p.m. ET / 12:00 p.m. PT.
Jul 26, 2021 09:05 am ET
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the presentation of new preclinical data linking P. gingivalis to increased levels of phospho-tau217, an emerging biomarker for Alzheimer’s disease. This research, along with new baseline data from its pivotal GAIN Trial, is being presented by the company at the Alzheimer's Association International Conference® 2021 (
Jul 23, 2021 08:00 am ET
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.
Jul 22, 2021 08:00 am ET
Cortexyme to Present New Data at AAIC 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that it will present two poster presentations covering an update from its pivotal Phase 2/3 GAIN Trial of atuzaginstat, in addition to new data demonstrating the upstream role that P. gingivalis plays in key pathology of Alzheimer’s disease, at the Alzheimer's Association International Conference® 2021 (
Jul 21, 2021 08:00 am ET
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced new preclinical data demonstrating efficacious dose range finding data for its lead drug candidate atuzaginstat (COR388) in periodontal disease in conjunction with its participation at the International Association for Dental Research (
Jul 19, 2021 08:00 am ET
Cortexyme to Host Symposium at AAIC 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that it will host a corporate sponsored symposium and dinner held in conjunction with the Alzheimer's Association International Conference® 2021 (
Jul 08, 2021 08:00 am ET
Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced that it will host a key opinion leader (KOL) webinar series on its lead drug candidate atuzaginstat (COR388), a lysine-gingipain inhibitor. The webinar series will be held in two parts: Part 1 will be on Friday, July 23, 2021, at 10:00 a.m. ET, and Part 2 will be on Friday, July 30, 2021, at 10:00 a.m. ET. The series is being conducted in conjunction with Cortexyme’s
Jun 01, 2021 08:00 am ET
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the presentation of updated baseline demographic and biomarker data at the American Society of Clinical Psychopharmacology (ASCP) 2021 Annual Meeting.
May 26, 2021 08:00 am ET
Cortexyme to Present at Investor Conferences in June 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate at the following virtual investor conferences in June 2021:
May 10, 2021 08:00 am ET
Cortexyme Provides Business Update and Reports First Quarter 2021 Results
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today provided an update on expected clinical data readouts and reported first quarter 2021 financial results.
May 04, 2021 08:00 am ET
Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company’s chief operating officer and chief financial officer, will participate in a fireside chat at the BofA Securities 2021 Healthcare Conference, a virtual event, on Tuesday, May 11, 2021, at 3:30 p.m. EDT (12:30 p.m. PDT).
Mar 25, 2021 08:00 am ET
Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, co-founder, and chair, will participate in a fireside chat at the Stifel 3rd Annual CNS Day, a virtual event, on Thursday, April 1, 2021, at 10:00 a.m. EDT / 7:00 a.m. PDT.
Mar 10, 2021 08:00 am ET
Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced Chris Lowe, the company’s chief operating officer and chief financial officer, will present at the Oppenheimer 31st Annual Healthcare Conference, a virtual event, on Tuesday, March 16, 2021, at 4:00 p.m. EDT / 1:00 p.m. PDT.
Mar 08, 2021 08:00 am ET
Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, announced that it has partnered with the Parkinson Study Group (PSG) to form an Advisory Board to leverage the group’s expertise and further develop the company’s Parkinson’s disease (PD) program. In addition, Cortexyme will present new data further demonstrating the role of Porphyromonas gingivalis (P. gingivalis) in the development of Alzheimer’s disease at AD/PD™ 2021, the 15th International Conference on Alzheimer’s & Parkinson’s Diseas
Feb 18, 2021 08:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Feb 15, 2021 09:13 pm ET
Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease
Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, received a letter from the U.S. Food and Drug Administration (FDA) stating that a partial clinical hold has been placed on atuzaginstat (COR388) impacting the open-label extension (OLE) phase of the company’s ongoing Phase 2/3 study, the GAIN Trial. Under the hold, no new participants will be enrolled in the OLE and currently enrolled OLE participants will be discontinued. Participants in the fully enrolled (N=643) double-blind, placebo-controlled randomized phase
Feb 10, 2021 04:06 pm ET
Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease on schedule to be announced in Q4 2021 and a pipeline of therapeutics for degenerative diseases, today announced a series of leadership appointments to support the continued advancement and commercial planning of atuzaginstat, as well as the company’s pipeline expansion and regulatory affairs capabilities.
Jan 26, 2021 08:00 am ET
Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced a corporate update and highlighted key milestones anticipated in 2021.
Dec 04, 2020 07:00 am ET
Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced that the independent Data Monitoring Committee (DMC) conducted a pre-planned interim analysis and recommended Cortexyme continue the Phase 2/3 GAIN Trial of atuzaginstat (COR388) as planned to the 1-year endpoint. 
Nov 12, 2020 04:30 pm ET
Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the third quarter 2020 and provided an update on its business.
Nov 05, 2020 08:00 am ET
Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer’s Disease Conference
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced the presentation of data demonstrating that in a subset of samples analyzed to date, a very high proportion of the adults with mild to moderate Alzheimer’s disease (AD) enrolled in the ongoing Phase 2/3 GAIN Trial of atuzaginstat have biomarker profiles consistent with AD, and all patients analyzed to date have evidence of immune response to systemic Porphyromonas gingivalis (P. gingivalis) infection,
Oct 19, 2020 08:00 am ET
Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced that its work will be the subject of abstracts at two upcoming scientific conferences: the 13th Clinical Trials on Alzheimer's Disease Digital Event (CTAD 2020; November 4-7) and the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC; November 9-14).
Sep 24, 2020 08:00 am ET
Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients
Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to moderate AD. The GAIN Trial’s protocol includes an interim analysis on the study’s co-primary cognitive and global endpoints after approximately 300 patients reach 24 weeks of treatment, and this interim analysis is expected to occur before year-end 2020. Top-line results of the GAIN Tr
Sep 09, 2020 08:00 am ET
Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 11:00 a.m. EDT / 8:00 a.m. PDT.
Aug 27, 2020 08:00 am ET
Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,730,826 relating to Cortexyme’s lead small molecule, atuzaginstat (COR388).
Aug 17, 2020 08:00 am ET
Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the second quarter 2020 and provided an update on its business.
Aug 14, 2020 08:00 am ET
Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 Patients
Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease (AD) has reached 500 patients toward the study’s previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to moderate AD. The GAIN Trial’s protocol includes an interim analysis on the study’s co-primary cognitive and functional endpoints after approximately 300 patients reach 24 weeks of treatment; this interim analysis is expected
Aug 06, 2020 04:05 pm ET
Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the following two investor conferences in August 2020:
Jul 29, 2020 08:00 am ET
Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen Dominy, M.D., the company’s chief scientific officer and co-founder, will participate in a fireside chat hosted by LifeSci Capital on Thursday, July 30 at 3:00 p.m. EDT / 12:00 p.m. PDT. The conversation will focus on the link between P. gingivalis and Alzheimer’s disease pathology.
Jul 28, 2020 06:09 pm ET
Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers As
Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases, today announced new preclinical data demonstrating the role of the bacterium P. gingivalis in Alzheimer’s disease (AD) and cardiovascular disease, providing a potential explanation for why the two diseases often occur together. Cortexyme also provided data demonstrating the therapeutic potential of its lead compound, atuzaginstat (COR388), in treating both diseases. This data, along with two other po
Jul 22, 2020 08:00 am ET
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases will be the subject of three research abstracts at the Alzheimer’s Association International Conference® 2020 (AAIC®). The largest international meeting dedicated to advancing dementia science, AAIC will be held as a
Jun 09, 2020 08:00 am ET
Cortexyme Announces “Atuzaginstat” Selected as First-in-Class Nonproprietary Name for COR388
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases, today announced that the International Nonproprietary Naming Committee of the World Health Organization (WHO) has selected atuzaginstat (pronounced “a too za’ gin stat”) as the proposed International Nonproprietary Name, or pINN, for the company’s lead product candidate COR388. Atuzaginstat is an oral, twice-daily investigational medicine in late stage clinical development for Alzheimer
May 27, 2020 08:00 am ET
Cortexyme to Present at the Jefferies Virtual Healthcare Conference on June 2, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 2:30 p.m. EDT / 11:30 a.m. PDT.
May 12, 2020 04:05 pm ET
Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the first quarter 2020 and provided an update on its business.
May 07, 2020 08:00 am ET
Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on Wednesday, May 13, 2020 at 1:00 p.m. EDT / 10:00 a.m. PDT.
May 06, 2020 08:30 am ET
Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the publication of research further documenting the ability of the pathogen Porphyromonas gingivalis to invade neurons and trigger Alzheimer’s-like neuropathology. The findings are to be published in the June 2020 issue of the Journal of Alzheimer’s Disease [JAD 75(4)]; an early online version of the paper is available now so
Apr 30, 2020 04:05 pm ET
Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary
Cortexyme, Inc. (Nasdaq: CRTX), a biopharmaceutical company developing treatments for Alzheimer’s disease (AD) and other degenerative diseases, today announced Caryn McDowell, J.D. will join the company’s executive leadership team as Chief Legal and Administrative Officer and Corporate Secretary, effective May 11, 2020. In this newly created role, Ms. McDowell will lead Cortexyme’s legal, corporate governance, compliance, human resources, and administrative functions.
Apr 06, 2020 08:30 am ET
Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will participate in a fireside chat at the virtual LifeSci Capital Alpha Series Conference on Thursday, April 9, 2020 at 1:00 p.m. EDT / 10:00 a.m. PDT.
Apr 02, 2020 08:00 am ET
Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced new data supporting the ability of the pathogen Porphyromonas gingivalis to invade brain cells and trigger characteristic Alzheimer’s pathology including synaptic loss, ultrastructural changes, and inflammation. The data is being presented this week as part of the Advances in Alzheimer’s and Parkinson’s Disease (AAT-AD/PD) Focus Meeting 2020, which was converted to a virtual meeting due
Mar 17, 2020 08:00 am ET
Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced financial results for the fourth quarter and full year 2019 and provided an update on its business.
Mar 16, 2020 08:00 am ET
Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 Patients
Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease has reached 300 patients toward the study’s previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of COR388, Cortexyme’s lead investigational medicine, in patients with mild to moderate Alzheimer’s disease. GAIN’s protocol includes an interim analysis for overwhelming efficacy on its co-primary cognitive and functional endpoints after 300 patients reach six months of treatment; this interim analysis is expected to occu
Feb 13, 2020 08:00 am ET
Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer’s Disease
Cortexyme, Inc. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company’s lead investigational medicine in development for mild to moderate Alzheimer’s disease (AD). The company conducted a Type C meeting with the FDA gathering agreement and feedback on development plans through NDA, including the Phase 2/3 GAIN Trial statistical analysis plan, metabolite characterization, nonclinical studies, population pharmacokinetics, and drug-drug interaction studies.
Feb 10, 2020 04:05 pm ET
Cortexyme Announces Closing of $125 Million Private Placement
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has closed its private placement offering. The Company issued 2,500,000 shares of common stock for a purchase price of $50.00 per share, resulting in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement primarily to advance clinical development, as well as
Feb 05, 2020 09:00 pm ET
Cortexyme Announces $125 Million Private Placement
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member of the Company’s Board of Directors in connection with a private placement of its common stock. The transaction is expected to result in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company plan
Jan 30, 2020 08:18 am ET
Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company’s Lead Investigational Medicine
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced the publication of new data in Pharmacology Research and Perspectives revealing further detail about the pharmacodynamics and utility of the company’s lead investigational medicine, COR388. The data provides additional evidence on the ability of COR388 to engage its target, the toxic proteases, or gingipains, released by the bacterium P. gingivalis and the closely related species
Jan 13, 2020 08:00 am ET
 Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer’s Disease
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced it is initiating an open-label extension study in the United States for its Phase 2/3 GAIN Trial of COR388 in subjects with mild to moderate Alzheimer’s disease (AD). Additionally, the GAIN Trial Data Monitoring Committee recently completed its first planned safety review and recommended continuation of the study as planned.
Jan 08, 2020 04:05 pm ET
Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder will present at the 3rd Annual Neuroscience Innovation Forum on Sunday, January 12, 2020 at 3:45 p.m. PST / 6:45 p.m. EST. The Forum will take place on the eve of the J.P. Morgan Healthcare Conference in downtown San Francisco.
Dec 07, 2019 01:00 pm ET
Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer’s Disease
Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentation of new data supporting the on-target activity of COR388, its lead investigational medicine, and linking the “gingipain hypothesis” for Alzheimer’s disease (AD) to the significance of the APOE gene as a major risk factor for the disease. Michael Detke, M.D., Ph.D., the company’s chief medical officer, detailed the results in an oral presentation (abstract #OC28) at the 2019 Clinical Trials in Alzheimer’s Disease (CTAD) meeting, which is being held December 4-7, 2019 in San Diego.
Nov 26, 2019 04:05 pm ET
Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 2:00 p.m. EST / 11:00 a.m. PST in Boston.
Nov 12, 2019 04:05 pm ET
Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced financial results for the third quarter 2019 and provided an update on its business.
Nov 01, 2019 08:00 am ET
Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer’s Disease 2019
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that its lead investigational medicine, COR388, will be the subject of an oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2019. The company will also host a lunch briefing on the preclinical and clinical data supporting COR388’s mechanism of action, as well as its evaluation in the ongoing Phase 2/3 GAIN trial. CTAD bri
Sep 26, 2019 08:00 am ET
Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced the start of screening in Europe for the GAIN (GingipAIN Inhibitor for Treatment of Alzheimer’s Disease) Trial, the company’s ongoing Phase 2/3 clinical study of lead investigational medicine COR388 in subjects with mild to moderate Alzheimer’s disease (AD). The international trial has been enrolling in the United States since the second
Jul 31, 2019 04:05 pm ET
Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chairman, and co-founder, will present at the Canaccord Genuity Growth Conference on Wednesday, August 7th, 2019 at 9:00 a.m. EDT (6:00 a.m. PDT) in Boston.
Jul 17, 2019 11:00 am ET
Cortexyme’s Approach to Addressing a Key Underlying Cause of Alzheimer’s Detailed at Alzheimer’s Association International Conference 2019
Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentation of clinical data that supports its ongoing work to pioneer a novel, disease-modifying therapeutic approach to treating a key underlying cause of Alzheimer’s and other degenerative diseases. In a poster presentation at the Alzheimer’s Association International Conference® 2019 (AAIC®), researchers highlighted the Phase 1b clinical development experience of COR388, the company’s lead investigational gingipain inhibitor, and provided an overview of the design for the GAIN trial, the company’s large, internationa
Jul 10, 2019 08:00 am ET
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2019
Cortexyme, Inc. (Nasdaq: CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases will be discussed in two research abstracts at the Alzheimer’s Association International Conference® 2019 (AAIC®). The conference, which is the largest international meeting dedicated to advancing dementia science, will be held July 14-18, 2019 in Los Angeles.
Jun 19, 2019 08:00 am ET
Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four new additions to its Clinical Advisory Board (CAB). Jeffrey Cummings, M.D., Sc.D., David Hosford M.D., Ph.D., Lon Schneider, M.D., M.S., and Pierre N. Tariot, M.D. join the CAB with deep and diverse experience in central nervous system (CNS) drug development. The newly expanded CAB will support Cortexyme as i
Jun 10, 2019 08:00 am ET
Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019
Cortexyme, Inc. (Nasdaq: CRTX) today announced that Casey Lynch, the company’s chief executive officer, chairman, and co-founder, will present at a National Academies of Science, Engineering, and Medicine workshop on the growing understanding of the relationship between pathogens and chronic disease this week. Ms. Lynch will provide an overview of Cortexyme’s work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases during “Breaking Down Silos: The Convergence
May 13, 2019 05:11 pm ET
Cortexyme, Inc. Announces Closing of Initial Public Offering and the Exercise of the Underwriters’ Option to Purchase Additional Shares
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced the closing of its initial public offering of 4,412,000 shares of its common stock at the public offering price of $17.00 per share, and the full exercise by the underwriters of their option to purchase 661,800 additional shares of Cortexyme’s common stock. The exercise of the option brings the total number of shares of
May 08, 2019 07:22 pm ET
Cortexyme, Inc. Announces Pricing of Initial Public Offering
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions. In addition, Cortexyme has granted the underwriters a 30-day option to purchase up to an additional 661,800 shares at the initial public

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.